BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP

巴尔的摩儿童艾滋病临床试验小组(BPACTG) 成立于1988年，是美国国家安全局调查人员之间的合作努力 约翰霍普金斯大学和马里兰大学巴尔的摩分校。AS 世界上两个主要的艾滋病毒感染儿童护理地点 巴尔的摩大都市区和马里兰州，BPACTG已经 该区域几乎所有初级和专科护理中心以及 为婴儿提供了最先进的艾滋病毒特异性治疗方法， 儿童、青少年和怀孕的母亲。 BPACTG中的两个站点在临床服务方面有着相同的目标 和研究：提供最高质量的全面护理 受艾滋病毒影响的家庭；研究感染艾滋病毒的机制 垂直获得性艾滋病毒感染的传播和发病机制； 开发和测试预防艾滋病毒的新治疗方法 疾病和艾滋病毒感染的传播。 BPACTG调查员积极参与ACTG的工作， 包括委员会和工作组。概念表和协议 开发和协议管理。BPACTG有50多名患者 积极参加ACTU方案，已有117人入伍 在最初四年半的活动中。在此描述的研究 计划在以下四年内每年招收35-40名新患者 建议的资金周期。拟议的研究将主要涉及 服务不足的患者群体：非裔美国人和女性。 特设工作组的优先领域是这项提案的关键内容。这个 BPACTG将继续参与围产期试验，试图 阻断艾滋病毒垂直传播，并提出更多 围产期传播决定因素的发展研究。 新的抗逆转录病毒药物的开发将是优先事项 BPACTG在未来四年内，将第一/第二阶段试验与拟议的 儿科药理学核心实验室。向感染艾滋病毒的青少年提供外展服务 将继续努力识别受感染的青少年和 将他们带入BPACTG护理网络。改进现有的 神经发育评估工具和新测试的发展 仪器被纳入临床核心，以及 发展研究组成部分。建立一个免疫学核心 疾病免疫标志物的实验室和发展研究 并提出了发展的建议。 过去的五年建立了一个有效的研究人员网络 以及BPACTG中为感染艾滋病毒的青年和孕妇提供服务的人员 这一地区的母亲们。这个团队有能力、组织和 与社区的联系是进行富有成效的研究所必需的 将有助于提供更新、更有效的治疗方法来预防艾滋病毒 传播和减轻艾滋病毒在这方面的负担 人口。

The Baltimore Pediatric AIDS Clinical Trials Group (BPACTG) was established in 1988 as a collaborative effort between investigators at The Johns Hopkins University and the University of Maryland at Baltimore. As the two predominant sites for care of HIV-infected children in the Baltimore metropolitan area and the state of Maryland, the BPACTG has been the center of nearly all primary and specialized care for the region and has provided access to the most advanced HIV-specific therapy for infants, children, teenagers, and pregnant mothers. Both sites in the BPACTG share the same goals in their clinical service and research: to provide comprehensive care of the highest quality to families affected by HIV; to conduct research into the mechanisms of transmission and pathogenesis of vertically-acquired HIV infection; and to develop and test new therapeutic modalities for the prevention of HIV disease and transmission of HIV infection. The BPACTG investigators participate actively in the ACTG effort, including committees and working groups. concept sheet and protocol development, and protocol administration. The BPACTG has over 50 patients actively participating in ACTU protocols, and 117 have been enrolled during the first 4 1/2 years of activity. The research described herein plans to enroll 35-40 new patients per year during the four years of proposed funding cycle. The proposed research will involve predominantly underserved patients groups: African-Americans and women. Areas of priority for the ACTG are key elements in this proposal. The BPACTG will continue to participate in perinatal trials attempting to interrupt vertical transmission of HIV, and propose additional developmental research into the determinants of perinatal transmission. Development of novel antiretroviral agents will be a priority for the BPACTG in the next four years, linking Phase I/II trials with the proposed pediatric pharmacology core laboratory. Outreach to adolescents with HIV will continue, with efforts directed at identifying infected teenagers and bringing them into the BPACTG care network. Refinement of existing neurodevelopmental assessment tools and development of new testing instruments is incorporated into the clinical core as well as developmental research components. Establishment of an immunology core laboratory and developmental research into immunologic markers of disease progression are proposed. The past five years have established an effective network of researchers and providers in the BPACTG who serve the HIV-infected youth and expectant mothers of this region. This group has the capabilities, organization, and linkages with the community necessary to conduct productive research which will help provide newer, more effective therapies to prevent HIV transmission and to ameliorate the burden of HIV disease in this population.